Of clinical relevance, epigenetic therapy approaches [76, 132, 133] that alter the expression of genes with the broad epigenetic domain must be cognizant that silencing these genes may make the cancer more aggressive as shown with SPRY4 in triple negative breast cancer. This evidence concerns the gene SPRY4 and triple-negative breast carcinoma.